The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%. PORTLAND, OR, UNITED STATES, January 30, 2025 ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

DAVENPORT & Co LLC reduced its position in shares of argenx SE (NASDAQ:ARGX – Free Report) by 5.1% during the fourth quarter, ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

The registrational Phase III study is a multicenter, open-label, single arm study in Japanese patients with IgA nephropathy, and is planned to confirm the efficacy and safety of sparsentan in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...